Community-driven development of a modified progression-free survival ratio for precision oncology
Objective Measuring the success of molecularly guided therapies is a major challenge in precision oncology trials.A commonly used endpoint is an intra-patient progression-free survival (PFS) ratio, defined as the PFS interval associated with molecularly guided therapy (PFS2) divided by the PFS interval associated with the last prior systemic therap